Cost-effectiveness of an insertable cardiac monitor to detect atrial fibrillation in patients with cryptogenic stroke - Université de Rennes Accéder directement au contenu
Article Dans Une Revue International Journal of Stroke Année : 2016

Cost-effectiveness of an insertable cardiac monitor to detect atrial fibrillation in patients with cryptogenic stroke

Eloi Marijon
Jean-Claude Deharo
Pierre Bordachar
  • Fonction : Auteur
Serge Boveda
Alex Diamantopoulos
  • Fonction : Auteur
Laura Sawyer
  • Fonction : Auteur
Gregory Yh Lip
  • Fonction : Auteur
Klaus Witte
  • Fonction : Auteur
Ben Brown
  • Fonction : Auteur
Maria Quiroz Angulo
  • Fonction : Auteur
Hans-Christoph Diener

Résumé

Background and aims Documentation of atrial fibrillation is required to initiate oral anticoagulation therapy for recurrent stroke prevention. Atrial fibrillation often goes undetected with traditional electrocardiogram monitoring techniques. We evaluated whether atrial fibrillation detection using continuous long-term monitoring with an insertable cardiac monitor is cost-effective for preventing recurrent stroke in patients with cryptogenic stroke, in comparison to the standard of care. Methods A lifetime Markov model was developed to estimate the cost-effectiveness of insertable cardiac monitors from a UK National Health Service perspective using data from the randomized CRYSTAL-AF trial and other published literature. We also conducted scenario analyses (CHADS 2 score) and probabilistic sensitivity analyses. All costs and benefits were discounted at 3.5%. Results Monitoring cryptogenic stroke patients with an insertable cardiac monitor was associated with fewer recurrent strokes and increased quality-adjusted life years compared to the standard of care (7.37 vs 7.22). Stroke-related costs were reduced in insertable cardiac monitor patients, but overall costs remained higher than the standard of care (£19,631 vs £17,045). The incremental cost-effectiveness ratio was £17,175 per quality-adjusted life years gained, compared to standard of care in the base-case scenario, which is below established quality-adjusted life years willingness-to-pay thresholds. When warfarin replaced non-vitamin-K oral anticoagulants as the main anticoagulation therapy, the incremental cost-effectiveness ratio was £13,296 per quality-adjusted life years gained. Conclusion Insertable cardiac monitors are a cost-effective diagnostic tool for the prevention of recurrent stroke in patients with cryptogenic stroke. The cost-effectiveness results have relevance for the UK and across value-based healthcare systems that assess costs relative to outcomes.
Fichier non déposé

Dates et versions

hal-03655296 , version 1 (29-04-2022)

Identifiants

Citer

Maria Soledad Ascoeta, Eloi Marijon, Pascal Defaye, Didier Klug, Frankie Beganton, et al.. Cost-effectiveness of an insertable cardiac monitor to detect atrial fibrillation in patients with cryptogenic stroke. International Journal of Stroke, 2016, 11 (3), pp.302-312. ⟨10.1177/1747493015620803⟩. ⟨hal-03655296⟩
15 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More